Last reviewed · How we verify
Insulin Humulin® NPH
Insulin Humulin NPH is a human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Insulin Humulin NPH is a human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Humulin® NPH |
|---|---|
| Sponsor | Geropharm |
| Drug class | Intermediate-acting human insulin |
| Target | Insulin receptor (IR) |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting human insulin formulation where protamine is added to slow absorption and extend duration of action. It works by mimicking endogenous insulin's effects on glucose metabolism, promoting cellular glucose uptake, glycogen synthesis, and inhibiting gluconeogenesis. The protamine suspension allows for a slower onset and longer duration compared to regular insulin, making it suitable for basal insulin coverage in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients. (PHASE4)
- Intranasal Insulin for COVID-19-related Smell Loss (PHASE3)
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (PHASE4)
- A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (PHASE1)
- Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method (NA)
- Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal (PHASE1)
- Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Humulin® NPH CI brief — competitive landscape report
- Insulin Humulin® NPH updates RSS · CI watch RSS
- Geropharm portfolio CI